Legalize59765 laws
59765 laws
- § 354. Veterinary feed directive drugs
- § 355. New drugs
- § 355a. Pediatric studies of drugs
- § 355b. Adverse-event reporting
- § 32. Lake George, Mississippi
- § 355c. Research into pediatric uses for drugs and biological products
- § 355c–1. Report
- § 355d. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers
- § 355e. Pharmaceutical security
- § 355f. Extension of exclusivity period for new qualified infectious disease products
- § 355g. Utilizing real world evidence
- § 355h. Regulation of certain nonprescription drugs that are marketed without an approved drug application
- § 355–1. Risk evaluation and mitigation strategies
- § 355–2. Actions for delays of generic drugs and biosimilar biological products
- §§ 311 to 323. Repealed. [Pub. L. 96–591, § 8(a)](/us/pl/96/591/s8/a), Dec. 24, 1980, [94 Stat. 3435](/us/stat/94/3435)
- § 356. Expedited approval of drugs for serious or life-threatening diseases or conditions
- § 356a. Manufacturing changes
- § 356b. Reports of postmarketing studies
- § 356c. Discontinuance or interruption in the production of life-saving drugs
- § 356c–1. Annual reporting on drug shortages
- § 356d. Coordination; task force and strategic plan
- § 356e. Drug shortage list
- § 356f. Hospital repackaging of drugs in shortage
- § 356g. Standards for regenerative medicine and regenerative advanced therapies
- § 356i. Prompt reports of marketing status
- § 356j. Discontinuance or interruption in the production of medical devices
- § 356k. Platform technologies
- § 356l. Advanced manufacturing technologies designation program
- § 356–1. Accelerated approval of priority countermeasures
- § 356–2. Accelerated approval Council
- § 357. Qualification of drug development tools
- § 358. Authority to designate official names
- § 359. Nonapplicability of subchapter to cosmetics
- § 360. Registration of producers of drugs or devices
- § 360a. Clinical trial guidance for antibiotic drugs
- § 360aa. Recommendations for investigations of drugs for rare diseases or conditions
- §§ 360aaa to 360aaa–6. Omitted
- § 360a–1. Clinical trials
- § 360a–2. Susceptibility test interpretive criteria for microorganisms
- § 360b. New animal drugs
- § 360bb. Designation of drugs for rare diseases or conditions
- § 360bbb. Expanded access to unapproved therapies and diagnostics
- § 360bbb–0. Expanded access policy required for investigational drugs
- § 360bbb–0a. Investigational drugs for use by eligible patients
- § 360bbb–1. Dispute resolution
- § 3104. Authorization of appropriations
- § 360bbb–2. Classification of products
- § 360bbb–3. Authorization for medical products for use in emergencies
- § 360bbb–3a. Emergency use of medical products
- § 360bbb–3b. Products held for emergency use